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Introduction
Amyloidosis represents a heterogeneous group of disor-
ders characterized by extracellular deposition of autolo-
gous fibrillary proteins which impair normal organ
function. Reactive AA type amyloidosis may complicate
autoinflammatory diseases (AID).
Objective
To evaluate and compare the renal biopsy findings and
clinical and laboratory parameters in patients with amy-
loidosis secondary to AID who have responded to the
anti-interleukin 1 (IL1) treatment.
Patients and methods
Two children with systemic juvenile idiopathic arthritis and
one with cryopyrin-associated periodic syndrome diag-
nosed as AA type amyloidosis were treated with anti-IL1
drugs and we have evaluated the course and management
of these patients for a follow-up of median 56 (41-56)
months. The renal biopsies at the time of diagnosis of amy-
loidosis and after the onset of anti-IL1 treatment were eval-
uated and compared according to the amyloid scoring and
grading system based on the histopathological findings.
Results
The median age of AID onset was three years, while the
patients were diagnosed to have amyloidosis at a median
of 12 years of age. The patients previously used nonsteroi-
dal anti-inflammatory drugs, corticosteroid, methotrexate,
azathioprine, infliximab, and intravenous immunoglobulin
treatments. After the diagnosis of amyloidosis, anakinra
was started. All three responded to anakinra treatment;
however, canakinumab was commenced in patient 3 since
anakinra caused local cutaneous reaction at the site of
drug administration. Proteinuria was improved in patients
after anti-IL 1 treatment. Control renal biopsies were per-
formed a median of three years later than the diagnosis of
amyloidosis. At the renal biopsy level, we have seen that
the renal amyloid prognostic score did not improve in
patient 1 and progressed in patient 2 and 3. The renal
amyloid grade has also progressed in patient 2.
Conclusion
To the best of our knowledge, this is the first series
showing progression of renal tissue damage after the
improvement of proteinuria with anti-IL 1 treatment in
AID-associated amyloidosis. After the development of
amyloidosis, it is crucial to control inflammation effec-
tively and prevent further amyloid accumulation in
patients with anti-inflammatory treatments such as anti-
IL1 drugs. However, new treatment strategies are needed
to target the amyloid deposits for patients with severe
organ involvement.
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